Incyte CORP Form 4 insider transactions

Thomas Tray of Incyte Corp reported transactions involving common stock and stock options on June 4, 2026.

Pablo Cagnoni of Incyte Corp reports a transaction involving common stock, with shares withheld for tax obligations.

Thomas Tray, Principal Accounting Officer at Incyte Corp, sold 2,051 shares of common stock on May 26, 2026.

Director Jean-Jacques Bienaime exercised 15,000 stock options and sold a portion to cover tax obligations.

Incyte Corporation director Paul J. Clancy reported transactions involving the purchase and sale of common stock and the exercise of a stock option.

Incyte Corporation's CMO, Steven H. Stein, has been awarded 44,124 performance shares based on achieved performance criteria, with vesting scheduled for July 2026.

Incyte Corporation reports that Pablo J. Cagnoni, President, Global Head of R&D, has earned performance shares based on achievement of specified criteria.

Baker Bros. Advisors LP and affiliated entities report transactions involving Incyte Corp. common stock and stock options, reflecting beneficial ownership changes.

Incyte Corp executive Suketu Upadhyay reports on stock awards, restricted stock units, and stock options granted on May 4, 2026.

Pablo Cagnoni, President of Global R&D at Incyte Corp, reported transactions involving the acquisition of common stock and employee stock options.

Incyte Corporation CEO William Meury has earned 125,000 performance-based shares following the achievement of pre-established performance criteria.

Incyte Corporation President and Global Head of R&D Pablo Cagnoni acquired 27,892 shares following the achievement of performance criteria.

Incyte Corporation's Chief Medical Officer Steven H. Stein has been awarded 39,049 shares of common stock following the achievement of performance criteria.

Director Julian C. Baker acquired 421 shares of Incyte Corporation common stock in lieu of quarterly director retainer fees.

Director Paul J. Clancy acquired 265 shares of Incyte Corporation common stock as part of a quarterly director retainer fee election.

Incyte Corp's EVP, GM of Dermatology US, Matteo Trotta, disposed of 537 common shares to cover tax obligations related to restricted stock unit settlement.

Incyte Corp's President of R&D, Pablo J. Cagnoni, exercised stock options and subsequently sold a portion of common stock on March 17, 2026, under a Rule 10b5-1 plan.

Incyte Corp's President of R&D, Pablo J. Cagnoni, exercised stock options and subsequently sold the acquired shares on February 19, 2026, under a pre-arranged plan.

Incyte EVP Michael James Morrissey reported the disposition of 185 common shares for tax withholding purposes at a price of $102.67 per share.

Incyte EVP Lee Heeson reported a disposition of 111 common shares to satisfy tax obligations at a price of $102.67 per share.

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, was granted 8,911 restricted stock units, which will vest 25% annually over four years.

Incyte Corp's President of R&D, Pablo J. Cagnoni, was granted 28,475 employee stock options with an exercise price of $106.21.

Incyte's EVP & Chief Medical Officer, Steven H. Stein, was granted 19,932 employee stock options with an exercise price of $106.21, vesting over three years starting July 2026.

Incyte Corp's EVP, Head of US Oncology, Mohamed Khairie Issa, was granted 14,237 employee stock options with an exercise price of $106.21.

Incyte Corp's EVP, GM of Dermatology US, Matteo Trotta, was granted 8,542 employee stock options with an exercise price of $106.21.

Incyte's Principal Accounting Officer, Tray Thomas, was granted 2,425 employee stock options with an exercise price of $106.21, vesting over three years.

Incyte's EVP & Chief Scientific Officer, Patrick A. Mayes, was granted 4,218 employee stock options with an exercise price of $106.21.

Incyte's EVP, Head of Tech. Operations, Michael James Morrissey, received a grant of 7,426 restricted stock units and subsequently disposed of 429 shares to cover tax withholding obligations.

Mohamed Khairie Issa, Incyte's EVP, Head of US Oncology, reported the sale of 10,856 common shares and a tax-related withholding of 8,264 shares, both executed under a Rule 10b5-1 plan.

Incyte's EVP and Chief Medical Officer, Steven H. Stein, sold 15,634 shares of common stock for $101.7 per share under a pre-arranged 10b5-1 trading plan.